Michael Dickinson, MBBS, DMedSc, on a Phase II Trial of Glofitamab in DLBCL

Michael Dickinson, MBBS, DMedSc, on a Phase Ib Trial of Glofitamab Plus Pola-R-CHP in DLBCLПодробнее

Michael Dickinson, MBBS, DMedSc, on ASH Glofitamab UpdatesПодробнее

Michael Dickinson, MBBS, DMedSc, on Glofitamab Combination Trials UnderwayПодробнее

Bispecific Antibodies in Lymphoma with Dr. Michael DickinsonПодробнее

The STARGLO trial: glofitamab in combination with gemcitabine and oxaliplatin in R/R DLBCLПодробнее

COALITION: glofitamab + R-CHOP or glofitamab + pola-R-CHP in high-risk DLBCLПодробнее

Michael Dickinson, MBBS, DMedSc, on Summer Conference Highlights in LymphomaПодробнее

Phase II study of glofitamab in patients with R/R LBCLПодробнее

Glofitamab induces durable complete remissions in patients with relapsed large B-cell lymphomaПодробнее

Updated results of glofitamab plus polatuzumab vedotin combination therapy in DLBCL, including HGBCLПодробнее

Insights into Phase I/II study assessing fixed-duration glofitamab treatment for R/R LBCLПодробнее

Glofitamab as a single agent in heavily pretreated patients with DLBCLПодробнее

Updates in bispecifics for DLBCL from ASH: glofitamab, odronextamab, epcoritamab & mosunetuzumabПодробнее

Impact of TMTV on PFS following glofitamab treatment in R/R DLBCLПодробнее

The current and future role of bispecifics in R/R DLBCL: epcoritamab, glofitamab & moreПодробнее

The benefits of glofitamab in R/R DLBCL post-CAR-T therapyПодробнее

The emerging potential of bispecific antibodies as monotherapy & in combination for B-cell lymphomaПодробнее

Glofitamab in R/R DLBCL: updated safety and efficacy dataПодробнее

ASH highlights: glofitamab in DLBCL & pirtobrutinib and epcoritamab in Richter's transformationПодробнее